Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20,788,527
-
Total 13F shares
-
167,154,299
-
Share change
-
+12,782,814
-
Total reported value
-
$2,258,638,117
-
Put/Call ratio
-
93%
-
Price per share
-
$13.51
-
Number of holders
-
223
-
Value change
-
+$158,722,470
-
Number of buys
-
106
-
Number of sells
-
110
Institutional Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q4 2021
As of 31 Dec 2021,
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) was held by
223 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
167,154,299 shares.
The largest 10 holders included
Invesco Ltd., BlackRock Inc., VANGUARD GROUP INC, PRIMECAP MANAGEMENT CO/CA/, WELLINGTON MANAGEMENT GROUP LLP, MAVERICK CAPITAL LTD, STATE STREET CORP, Bellevue Group AG, Camber Capital Management LP, and FIRST TRUST ADVISORS LP.
This page lists
225
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.